Queensland delegates
Connect with top Australian representatives from Queensland’s thriving biomedical sector at BIO 2024 in San Diego, California. This will be the 25th year a Queensland team has attended this event, the world’s largest annual gathering of the biotechnology industry.
Queensland’s Government and Industry Bodies
-
Queensland Government
Department of State Development and Infrastructure
Queensland Government
Department of State Development and Infrastructure
The Department of State Development and Infrastructure is a Queensland Government department that brings together the functions of infrastructure with economic, regional and industry development to create great places to live, work and play in Queensland. The department is responsible for Queensland’s Biomedical 10-Year Roadmap and Action Plan, setting out our vision for Queensland to be a globally competitive Asia-Pacific biomedical industry hub by 2027.
-
Queensland Government
Trade and Investment Queensland (TIQ)
Queensland Government
Trade and Investment Queensland (TIQ)
Trade and Investment Queensland is the Queensland Government’s dedicated global business agency, helping Queensland exporters take their products to world markets and promoting Queensland as the perfect place for investment.
TIQ facilitates personalised connections to drive global business opportunities for export markets, and attract international investors, buyers and talent to Queensland, Australia.
-
Queensland Investment Corporation
Queensland Investment Corporation
QIC Real Estate
QIC is a trusted investment manager and adviser providing risk adjusted returns for the clients it serves. As one of the nation’s leading institutional investment managers, QIC delivers alternative real asset solutions across infrastructure, real estate, private debt, private equity and natural capital, in addition to a liquid market offering, for approximately 115 Australian and global clients. It also acts as the Queensland Government’s independent investment advisor, managing a fully-funded Defined Benefit scheme and the Queensland Future Fund, both of which deliver on the State’s long-term investment objectives. QIC has A$106bn in assets under management (as at 31 Dec 2023) and are headquartered in Brisbane, Australia, with offices in Sydney, Melbourne, New York, San Francisco, London and Singapore.
Brisbane Economic Development Agency (BEDA)
Brisbane Economic Development Agency (BEDA)
BEDA drives investment demand for the city of Brisbane. As Brisbane's champion – BEDA works with government and private sector organisations to support global investors to leverage economic opportunities within Brisbane. BEDA also leads the city’s MedTech Initiative scaling local “first in class” start-ups by fast tracking connections with international partners – capital investment and distribution.
Headquartered in Brisbane, Australia, BEDA supports full market entry and capital strategies for investors providing:
- Market Data and Insights – Sector specific
- Liaison to Government – Local, State & Federal
- Liaison to Industry, Institutions and Advisory
- Incentive & Grant Information
- Front Door to Innovation – Pathway to “First in Class” MedTech Breakthroughs
- Property & Infrastructure Insights – Confidential site selection support
- Advocacy for Development Applications – Local and State Authorities
Life Sciences Queensland (LSQ)
Life Sciences Queensland (LSQ)
Life Sciences Queensland Limited (LSQ) is a Queensland peak body that offers opportunities for industry stakeholders to come together and cooperate to grow their businesses and help create a dynamic, internationally competitive, and sustainable life sciences industry in Queensland, Australia.
LSQ is helping to shape the strategic direction of the industry in Queensland and influence public policy:
- We are a crucial communicator within the sector, celebrating achievements and reinforcing and amplifying key messages.
- We proudly represent and advocate for our members and the sector.
- We open doors for our members by providing marketing and networking opportunities.
- We connect the sector, bringing people together to create a more cohesive and collaborative ecosystem within Queensland, and support new entrants to navigate the sector.
Queensland’s universities and research institutes
-
Griffith Enterprise
Griffith Enterprise
Griffith is one of Australia's leading research universities
Working in our world-class research centres, institutes and schools, our researchers are driven to better understand our world and improve people’s lives. Our research strengths span a broad spectrum of areas, from chronic diseases to criminology and Asian politics to the arts. Griffith researchers are at the forefront of discovery.
Our experts work in research centres developing new knowledge in a range of specialist areas including medicine and healthcare, emerging technologies, social innovations, culture, learning and the arts, the environment, and governance and policy development. Most of these institutes and centres align with our four academic groups, with their cutting-edge research helping to inform our degrees, allowing students to gain the latest knowledge and learn alongside people making history in a wide range of research fields.
-
Griffith Institute for Drug Discovery (GRIDD)
Griffith Institute for Drug Discovery (GRIDD)
GRIDD is a Griffith University research institute with a focus on early stage and pre-clinical drug discovery.
GRIDD’s aim is to utilise its unique resources, dedicated researchers and international partnerships to drive the discovery and development of revolutionary new treatments to improve human health and wellbeing.
We are currently focusing on a number of key discovery areas, including cancer, infectious diseases, Parkinson’s disease, drug resistance and spinal cord injury repair. Innovating at the cutting-edge of both chemistry and biology, we have ongoing established partnerships where we collaborate with local and national health institutions, governments, academia, industry, not-for-profit organisations and communities to create knowledge that transforms lives.
GRIDD is home to two significant resources in Compounds Australia and NatureBank. Compounds Australia is the nations’ industry standard compound curation facility, unmatched in the Southern hemisphere and a leader globally. NatureBank is Australia’s largest collection of raw biota, processed into large extract and fraction libraries. Both resources are available to researchers and industry worldwide that, like GRIDD, are seeking to discover new treatments and cures for debilitating illnesses.
-
Griffith University
Griffith University
Griffith is one of Australia's leading research universities
Since 1975, our teaching and research have been focused on addressing the most important social and environmental issues of our time. Today, that mission is as relevant as ever.
Social and environmental responsibility drive everything we do, from pioneering teaching in modern Asian studies and environmental science to our long-time support for First Peoples, social justice and sustainable practices.
Consistently ranking in the top 2 per cent of universities globally, our degrees are designed with industry in mind, the future in our sights, and social impact at heart.
With more than 55,000 students, our community spans five campuses across South East Queensland plus our Digital campus, complemented by a global alumni network of over 200,000 graduates.
-
Institute for Glycomics
Institute for Glycomics
The Institute for Glycomics is a world leader in the discovery and development of next-generation drugs, vaccines and diagnostics that fight diseases of global impact.
Established in 2000, we’re the only institute of its kind in Australia and one of only a handful in the world.
We engage globally with industry, philanthropic organisations, government and other premier research institutes to build the human capital driving healthcare solutions that address some of the world’s most intractable diseases.
Our multidisciplinary research primarily targets prevention and cures for infectious diseases, cancer and neurodegenerative disorders, with a focus on translational research.
-
QIMR Berghofer Medical Research Institute
QIMR Berghofer Medical Research Institute
QIMR Berghofer Medical Research Institute is an independent medical research institute
QIMR Berghofer Medical Research Institute (QIMR-B) has an outstanding and established track record of delivering internationally leading health and biomedical breakthroughs over almost eight decades. Its research performance has been underpinned by excellence and impact, contributing to improved health outcomes. Its collaborative research programs in cancer, infectious diseases, chronic inflammation, genetics of disease, population health, mental health and neuroscience address the foremost health challenges in the region and the world. Research programs at QIMR Berghofer respond to health challenges arising from social and environmental factors and aim to advance Aboriginal and Torres Strait Islander health equity.
QIMR-B is one of only two Australian institutes included in the Nature Index of the world's top 40 not-for-profit science institutions (placed first in Australian, 33rd globally). In 2023 the Institute produced 621 publications across prestigious journals such as Nature Genetics, Nature Communications, Cell Reports, Brain, and British Medical Journal.
For over two decades, Q-Gen at QIMRB has been pivotal in translating cellular immunotherapy research into early-phase clinical trials, collaborating with global partners to develop treatments for cancer, infectious diseases, and autoimmune disorders. Our TGA-approved GMP manufacturing facility, Q-Gen Cell Therapeutics, plays a vital role in providing potentially life-saving cell therapies to critically ill patients through the TGA’s Special Access Scheme.
In response to escalating global demand for trusted partners in clinical trials and innovative solutions, QIMR Berghofer proudly extends its hand in collaboration. We welcome partnerships with biotech, pharma, universities, and medical research institutes worldwide, offering expertise in planning, preparation, and prevention of life-threatening diseases. Together, we aim to foster strong institutional collaborations, building a global ecosystem for knowledge exchange and mentoring opportunities.
-
Queensland University of Technology
Faculty of Health, Centre for Genomics and Personalised Health
Queensland University of Technology
Faculty of Health, Centre for Genomics and Personalised Health
QUT has forged an enviable reputation as ""the University for the Real World"" leading to its inclusion in THE (Times Higher Education) and QS World University Rankings as one of the top 200 universities in the world. Integral to this reputation are the many industry partnerships which underpin our research platform, working to fulfil many of the United Nations Sustainable Development Goals, including renewable energy, food security, educational development, climate and health.
QUT holds particular strengths in genomics and personal health, biomedical technologies (joint biomechanics, cell and tissue engineering, medical devices), microbiome research, agriculture and bioeconomy (bananas, biofuels, synthetic biology), robotics and AI, data science, digital media.
-
Queensland University of Technology
Business Development
Queensland University of Technology
Business Development
QUT has forged an enviable reputation as ""the University for the Real World"" leading to its inclusion in THE (Times Higher Education) and QS World University Rankings as one of the top 200 universities in the world. Integral to this reputation are the many industry partnerships which underpin our research platform, working to fulfil many of the United Nations Sustainable Development Goals, including renewable energy, food security, educational development, climate and health.
QUT holds particular strengths in genomics and personal health, biomedical technologies (joint biomechanics, cell and tissue engineering, medical devices), microbiome research, agriculture and bioeconomy (bananas, biofuels, synthetic biology), robotics and AI, data science, digital media.
-
The University of Queensland
The University of Queensland (UQ) is one of Australia’s leading research and teaching institutions.
The University of Queensland
The University of Queensland (UQ) is one of Australia’s leading research and teaching institutions.
We strive for excellence through the creation, preservation, transfer and application of knowledge. For more than a century, we have educated and worked with outstanding people to deliver knowledge leadership for a better world.
UQ ranks among the world’s top universities, as measured by several key independent rankings, including the U.S. News Best Global Universities Rankings 2023 (36), the Performance Ranking of Scientific Papers for World Universities 2023 (37), CWTS Leiden Ranking 2023 (35), QS World University Rankings 2024 (43), Academic Ranking of World Universities 2023 (51), and Times Higher Education World University Rankings 2024 (70).
213 Fellows of Australia’s 5 learned academies – AAS, AAHMS, ASSA, ATSE, and AAH – are UQ staff (including honorary and adjunct appointments) and emeritus professors.
UQ is one of only 4 Australian members of the global Universitas 21, a founding member of the Group of Eight (Go8) universities, and a member of Universities Australia.
UQ has a strong focus on teaching excellence, having won more Australian Awards for University Teaching (AAUT) than any other university in the country and attracting the majority of Queensland's highest academic achievers, as well as top interstate and overseas students.
We are committed to excellence in learning experiences and outcomes for our students.
The University’s outstanding 332,000+ alumni include a Nobel laureate, an Academy Award winner, and leaders in government, law, science, public service and the arts. The University celebrates its alumni as its greatest assets. Their achievements reflect well on the University and, in return, we work hard to strengthen our reputation.
-
The University of Queensland
Institute for Molecular Bioscience
The University of Queensland
Institute for Molecular Bioscience
The Institute for Molecular Bioscience (IMB) is Australia’s #1 research institute. Created through merging a molecular and cellular biology centre with a drug discovery centre, IMB capabilities span genomics, biology and chemistry, encompassing basic discovery science to translational research. IMB tackles the diseases that plague people, animals and crops and has a track record of partnering to deliver translational outcomes, with spinouts including Protagonist Therapeutics and Inflazome. Expertise includes pharmacogenetics and statistical genetics, AI diagnostics, drug discovery and medicinal chemistry, preclinical research models and human studies. Disease foci include cardiovascular disease (stroke and heart attack), neurological disorders (Alzheimers, Parkinsons, and mental health), inflammation (particularly inflammasome-driven), endometriosis, antimicrobial resistance, genetic diseases, cancer, pain, and vaccines and diagnostics (bacterial, viral, parasitic).
-
The University of Queensland
The Queensland Emory Drug Discovery Initiative
The University of Queensland
The Queensland Emory Drug Discovery Initiative
The Queensland Emory Drug Discovery Initiative (QEDDI) is a small molecule drug discovery and development group dedicated to translating academic biomedical research into new medicines.
QEDDI is a business unit of UniQuest and the only example of its kind in an Australian university. QEDDI has an industry-experienced team dedicated to advancing biomedical research into new drug candidates to enable commercial partnerships and accelerate new drug development.
-
The University of Queensland
BASE mRNA Facility
The University of Queensland
BASE mRNA Facility
The BASE mRNA facility, at AIBN, UQ, helps scientists build new mRNA vaccines and therapies. We have experience making hundreds of mRNAs, and offer end-to-end services, including design, manufacture and LNP formulation of mRNA. We also provide off-the-shelf mRNA reagents and helpful advice. BASE scientists have a passion for mRNA. Our team have research interests in manufacturing and process development, bioinformatic design and analysis, and mRNA drug discovery and development.
Please contact us if you would like support developing new mRNA vaccines and therapies. The BASE facility has experience producing hundreds of mRNAs and offers end-to-end services, including the design, manufacture, and LNP formulation of mRNA for research and pre-clinical use, with clinical mRNA manufacturing facilities set to open in 2024.
-
The University of Queensland
Government Partnerships and Policy
The University of Queensland
Government Partnerships and Policy
The University of Queensland (UQ) is one of Australia’s leading research and teaching institutions. We strive for excellence through the creation, preservation, transfer and application of knowledge. For more than a century, we have educated and worked with outstanding people to deliver knowledge leadership for a better world.
UQ ranks among the world’s top universities, as measured by several key independent rankings, including the U.S. News Best Global Universities Rankings 2023 (36), the Performance Ranking of Scientific Papers for World Universities 2023 (37), CWTS Leiden Ranking 2023 (35), QS World University Rankings 2024 (43), Academic Ranking of World Universities 2023 (51), and Times Higher Education World University Rankings 2024 (70).
213 Fellows of Australia’s 5 learned academies – AAS, AAHMS, ASSA, ATSE, and AAH – are UQ staff (including honorary and adjunct appointments) and emeritus professors.
UQ is one of only 4 Australian members of the global Universitas 21, a founding member of the Group of Eight (Go8) universities, and a member of Universities Australia.
UQ has a strong focus on teaching excellence, having won more Australian Awards for University Teaching (AAUT) than any other university in the country and attracting the majority of Queensland's highest academic achievers, as well as top interstate and overseas students.
We are committed to excellence in learning experiences and outcomes for our students.
The University’s outstanding 332,000+ alumni include a Nobel laureate, an Academy Award winner, and leaders in government, law, science, public service and the arts. The University celebrates its alumni as its greatest assets. Their achievements reflect well on the University and, in return, we work hard to strengthen our reputation.
-
The University of Queensland
Faculty of Science
The University of Queensland
Faculty of Science
The Faculty of Science has a world-class reputation, ranking #4, #6 and #10 in the world for agriculture; for environment and ecology; for Biotechnology respectively. The Faculty has made significant achievements in microbiology, plant and animal science, and biology and biochemistry. Their biotechnology research spans several areas, including antibody engineering for cancer and inflammatory diseases, drug delivery systems, tissue engineering, vaccine design, and the development of diagnostic assays for various pathogens. There is also a focus on the discovery and development of antibiotics, antivirals, antifungals and biopesticides. Professor Ian Frazer and Dr Jian Zhou’s groundbreaking development of the cervical cancer vaccine took place in UQ’s Faculty of Science.
-
The University of Queensland
Australian Institute for Bioengineering and Nanotechnology (AIBN)
The University of Queensland
Australian Institute for Bioengineering and Nanotechnology (AIBN)
AIBN is world-renowned in mapping the processes of biology at the nanoscale. We work at the gene, genome and protein level to manufacture new materials, medicines and fuels. We partner with industry to lead advances in vaccine development for chronic and infectious diseases, mRNA design and production, precision nanomedicine, drug design and delivery, advanced biomanufacturing and biomass conversion, and stem cell and regenerative engineering.
-
The University of Queensland
Queensland Brain Institute
The University of Queensland
Queensland Brain Institute
The Queensland Brain Institute (QBI) is a world-leader in brain research, devoted to a fundamental understanding of how the brain works, focusing on five key areas - dementia and ageing, brain injury, brain development and plasticity, mental health and cognition and behaviour.
-
Translational Research Institute
Translational Research Institute
The Translational Research Institute (TRI) is a unique, Australian-first initiative of ‘bench to bedside’ medical research.
TRI combines clinical and translational research to advance progress from laboratory discovery to application in the community.
The TRI facility gives early-phase start up biotech companies time to establish, build, test and develop their products and provides a supportive environment to advance medical discoveries to healthcare solutions. In response to the lack of scale-up manufacturing facilities in Australia, TRI has secured funding to build Translational Manufacturing@TRI (TM@TRI), Australia’s first scale-up biomedical manufacturing facility supporting mid-stage biotech companies as they mature and manufacture products for Phase II and III clinical trials studies.
-
UniQuest Pty Limited
UniQuest Pty Limited
UniQuest is the commercialisation company of UQ.
UniQuest is the commercialisation company of UQ. In partnership with UQ’s researchers, we create impact through the commercialisation of UQ intellectual property. UniQuest’s track record positions UQ as the leader of research commercialisation in Australasia. Our expertise includes IP protection and management, start-ups and licensing, commercial negotiation and access to investment capital.
-
University of the Sunshine Coast
University of the Sunshine Coast
Clinical Trials
University of the Sunshine Coast (UniSC) Clinical Trials is an expansive network of five sites in Queensland (Australia), committed to improving access to clinical trials across our communities.
Our network of sites conducts studies in house and through a decentralised clinical trial (DCT) capability with primary, specialist, and urgent care in metropolitan and regional communities. A team of over 125 professionals including 22 medical investigators supports industry sponsors to undertake early to late phase including healthy volunteer confinement protocols. We conduct trials in a range of indications and therapeutic areas including vaccines, infectious disease challenge models (malaria), chronic diseases, haematology, and oncology.
Queensland's biomedical businesses
-
360biolabs
360biolabs
360biolabs stands as the preeminent specialty laboratory in the APAC region.
360biolabs offers a comprehensive suite of services to meet all your global clinical trial needs. Our expertise encompasses pharmacokinetic (PK) analysis across biologics, small molecules, peptides, and proteins, as well as a diverse array of pharmacodynamic (PD) endpoints such as flow cytometry, biomarkers, molecular assays, ELISpot, and virological endpoints, including neutralization along with central lab services in a rigorously quality-assured environment compliant with GLP, GCP, and ISO/IEC 17025 standards.
Backed by a team of seasoned scientific and QA professionals, we ensure the highest standards of scientific rigor, data integrity, and regulatory compliance across all stages of clinical development. Countless top global pharmaceutical and biotech companies trust us as their partner of choice. Our unwavering commitment to precision, punctuality, and regulatory excellence accelerates the delivery of your therapeutic breakthroughs to patients worldwide.
-
Alliance Pharma Pty Ltd trading as Resolian
Alliance Pharma Pty Ltd trading as Resolian
Resolian is a leading global Bioanalytical CRO providing specialized services in GxP and non-regulated bioanalysis, drug metabolism/pharmacokinetic (DMPK), and GMP CMC analytical and materials science. Comprised of the former Alliance Pharma Inc, Drug Development Solutions Ltd, and Denali Medpharma labs and powered by a team of more than 500 experts across the US, UK, Australia, and China, Resolian supports pharma and biotech companies’ programs throughout the entire drug development continuum.
Resolian's specialized solutions include small and large molecule LC-MS/MS bioanalysis, PK immunoassays for large molecules, immunogenicity, biomarkers, cell-based assays, and drug metabolism. These solutions are delivered through Resolian's dedicated global laboratories, equipped with state-of-the-art technology and ready to meet client needs for preclinical studies as well as regional or global clinical programs.
We are committed to delivering high-quality results and ensuring compliance with regulatory requirements. Its team of experts works closely with clients to develop customized solutions for each specific program requirements. A trusted partner for pharmaceutical and biotech companies seeking specialized support in drug development, Resolian's extensive expertise, advanced technology, and commitment to quality combine to fully deliver for companies of all sizes and at any stage of the drug development process.
-
Amivas Australia Pty Ltd
Amivas Australia Pty Ltd
AMIVAS is a US, Australian, and European joint venture.
AMIVAS is focused on the development and commercialisation of therapeutics for the treatment of life-threatening diseases with offices in the US, Australia and Ireland. AMIVAS manufactures in North America and our partners in Canada, USA and Europe package and supply our product to hospitals and patients in need.
AMIVAS’ vision was formed in response to the urgent need for a US and Europe- based firm to assume responsibility for the manufacture and distribution of Artesunate, for the treatment of severe malaria after quinidine gluconate was discontinued in 2019. With the US Food and Drug Administration (FDA) approval of its first commercial product on May 26, 2020, AMIVAS is proud to join the global effort to fight and eradicate malaria.
-
ARM Hub
ARM Hub
Advanced Robotics for Manufacturing Hub
ARM Hub is Australia's first manufacturing research and development organisation and an independent, not-for-profit innovation centre with a mission to accelerate the industry's uptake of next-generation advanced technologies. This includes robotics, artificial intelligence and design-led manufacturing.
-
Beyond Drug Development
Beyond Drug Development
Beyond is an Australian-based, privately owned, early-phase clinical research organization.
Beyond supports small-to-medium biotech and pharmaceutical companies across the globe. With a team averaging 20 years' experience in Early Phase research, we offer dedicated and innovative support to our clients whether in the preclinical drug development stage, or moving right through to the clinic and "Beyond".
-
BIO-BKN
BIO-BKN
BIO-BKN Pty Ltd is a medical-device company.
BIO-BKN Pty Ltd is a medical-device company committed to delivering clinically proven, cost-effective products allowing patients to actively heal and return to full activity sooner and safer following debilitating wound, ligament and tendon injuries. Bio BKN has developed a proprietary marine collagen platform technology with unique and versatile capabilities in wound care and orthopaedic applications. Its lead prototype product, a 3D printed marine collagen mesh for wound products and advanced tissue engineering applications will address modern healthcare needs. Bio BKN is seeking support to expand our platform to the next stage of development including further animal studies and generating data required for regulatory approvals in target markets.
-
Biostate Pty Ltd
Biostate Pty Ltd
Professional Director and Strategic Advisory services in life sciences and the health sector.
Professional Director and Strategic Advisory services in life sciences and the health sector.
-
Brandon Capital
Brandon Capital
Brandon Capital is ANZ’s leading life science venture capital firm.
Brandon Capital supports the commercialisation of promising medical research into therapies that generate returns and improve patients’ lives.
With 25 active companies in its portfolio and over $1 billion FUM, Brandon has taken a leading role in transforming world-leading science into world-leading businesses.
Unique deal-sourcing model that offers Brandon Capital proprietary deal flow for the nation’s most innovative biotechs, and positions the firm as an experienced partner to support teams from idea to IPO on their company-building journeys.
-
CCRM Australia
CCRM Australia
CCRM Australia accelerates the commercialisation of regenerative medicine therapies and related technologies.
CCRM provides specialist expertise, funding opportunities and connections between industry, clinicians, researchers, and other key stakeholders. CCRM Australia offers a number of market consulting services to understand and validate the potential of their technology, such as identifying problems and unmet needs, determining the ideal customer profile and market size, understanding the competitive landscape and creating a Target Product Profile. Our services extend to address any challenges that lie along the route to market from preclinical, clinical trials, process development and cGMP manufacturing.
-
Clinials Global Pty Ltd
Clinials Global Pty Ltd
The AI-powered platform is a copilot that offers continuously refined, updated, and expanded tools. This tool was designed to prioritize the creation of clear, patient-oriented materials in plain language, ensuring cultural diversity and localization (including multiple languages). It is also used for conducting protocol analysis, communicating with stakeholders, feasibility studies, and more. Employing a dynamic, holistic participant recruitment solution early in the life of a trial, could save millions of dollars.
-
Cytiva
Cytiva
Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics.
Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage that can be traced back of years, and recently welcomed the life sciences business of Pall into our family.
Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, novel cell and gene therapies, and new technologies, such as mRNA. By uniting the life sciences business of Pall with Cytiva, we can better serve our customers and provide them with the technologies and expertise needed to go from pre-clinical research to commercial production.
-
Data & Knowledge Enterprise (DKE) Pty Ltd
Data & Knowledge Enterprise (DKE) Pty Ltd
We are a data and AI service company, optimized for Generative AI helping
We are a data and AI service company, optimized for Generative AI helping small and large businesses. At DKE, we believe data and AI is for everyone and organizations deserve access to its transformative potential. That's why we've developed a service-based model that makes AI accessible, affordable, secure and easy to use for businesses of all sizes.
-
De Motu Cordis Pty Ltd
De Motu Cordis Pty Ltd
De Motu Cordis Pty Ltd (DMC) is producing a needle-free inhalable adrenaline device for the urgent treatment of anaphylaxis - Where Every Second Counts.
De Motu Cordis Pty Ltd (DMC)'s needle-free inhalable adrenaline device for the urgent treatment of anaphylaxis is the first product of a platform technology of drug delivery for medical emergencies.
We have grown to a clinical stage company with in-house expertise in pharma, engineering and emergency care medicine. We are collaborating with best-in-class at a global level having developed a new dry powder inhaler from the ground up.
-
FB Rice
FB Rice
Since being founded more than 70 years ago, FB Rice become Australia’s most trusted intellectual property firm with offices across the country and a well-established presence in New Zealand and South-East Asia.
Today, we combine world-leading expertise across biotechnology, chemistry, computer and electrical sciences, engineering and medical devices with integrity and a determination to help clients achieve their goals.
We pride ourselves on our expertise and our ability to make our clients feel comfortable and respected at every stage of the process. We’re real people who build partnerships based on trust by being open, approachable and totally focused on clients’ needs.
At FB Rice, we champion innovation and create value.
-
Fovero Therapeutics
Fovero Therapeutics
Fovero Therapeutics is a pre-clinical stage biotechnology company with a portfolio of novel immunotherapies for treating immuno-oncology resistant cancers and autoimmunity. The company’s lead immunotherapy, FT002, has potential to be a first-line, single agent therapy for colon cancer, which has a great unmet need.
In 2020, the total population of MSS patients, in 8 major markets, was approximately 800,000. Assuming, ~50% resistance to current therapies, and cost of US$224K/patient, the total market opportunity would be ~US$8.9B. It would also address an unmet need for triple negative breast cancer.
Fovero Therapeutics has raised AU$0.5M in non-dilutive funds from Brandon Biocatalyst, AU$0.69M from philanthropy and US$0.75M from US DoD to progress the understanding of FT002’s mode of action. FT is seeking US$12
-
Gelomics
Gelomics
Gelomics accelerates drug development by enabling pharmaceutical companies to grow human tissue models as an ethical, cost-effective, and highly predictive alternative to animal experiments. Addressing a US $50bn+ market opportunity, the company has achieved significant traction in 22 international markets, acquiring 300+ return customers with >80% demo-to-sales conversion and >20% MoM revenue growth. Gelomics is actively seeking distributors, customers, investors, and strategic partners to support our strategic entry in the US market. "
-
Graythan Regulatory Services Pty Ltd
Graythan Regulatory Services Pty Ltd
Graythan Regulatory Services (GRS) was established in 2017 to offer consulting services to support the biopharmaceutical industry. Our team has over 75 years of collective experience in the pharmaceutical industry with a specialty in readying stalled or legacy products to swiftly enter the clinic or gain marketing approval.
Over time, we grew to establish one of Brisbane’s only non-university-based Institutional Biosafety Committee (IBC) to provide classified advice, and formally review license applications on gene technology in Australia before submitting them for the Office of Gene Technology Regulator (OGTR) evaluation.
Our beginnings started when our founder saw the need for expert advice on regulatory and commercialisation pathways for emerging biotechnology. His wealth of experience in drug and vaccine development built the foundations for GRS to thrive.
-
HopgoodGanim Lawyers
HopgoodGanim Lawyers
HopgoodGanim Lawyers is a leading Australian mid-tier legal firm. We are recognised for the exceptional outcomes we deliver to our clients in our key priority markets and our superior approach to client service. Our firm includes over 300 staff with 40+ partners and we operate nationally and internationally with a focus on Asia from our two key locations of Brisbane and Perth.
Brett Nelson is a Director - Patents (USA qualified) in HopgoodGanim’s Intellectual Property, Technology and Cyber Security team.
He is highly experienced in complex IP portfolios and all phases of the patent life cycle, including patent preparation and prosecution, client counselling, due diligence for acquisitions and divestitures. With over twenty years of experience across Europe, China, Greater Asia, Australia and the United States, Brett is uniquely placed to assist clients in building and understanding IP portfolios.
-
James & Wells Intellectual Property
James & Wells Intellectual Property
Our life sciences team is consistently regarded as the leading choice for developing and implementing IP strategy by some of Australasia’s most innovative universities, start-ups, and research organisations.
James & Wells has an experienced team of life science specialists, with proven research experience across a range of life sciences including immunology, gene therapy, antibodies, cell therapies, synthetic medicinal chemistry, drug development and repurposing, cell biology, microbiology, vaccines and diagnostics.
Through defending the patent rights of our clients before the courts and patent offices of both Australia and New Zealand we are uniquely placed to advise innovators on established strategies for success. In the ever-evolving life sciences sector, our team also have the experience, expertise and confidence to carve out effective new strategies for overcoming complex hurdles in newly developing areas.
In order to keep abreast of industry trends and be at the forefront of life sciences innovation, James & Wells is an active member of AusBiotech, Life Sciences Queensland, Biotech New Zealand and Natural Health Products NZ. We understand the life sciences industry of today, and where it will be, tomorrow.
-
Kimaritec Pty Ltd
Kimaritec Pty Ltd
Kimaritec is developing new therapies for cancer, by manipulating the cancer cell’s protein recycling pathway to drive protein degradation of critical oncoproteins. Cancer remains a disease with high unmet medical need, with many patients succumbing to tumours which become unresponsive to current therapy. Clinicians and patients are looking for new approaches to eradicate or slow the progression of cancer. Kimaritec is taking a novel approach to selectively degrade proteins important for cancer growth and metastasis. It is hoped that by harnessing this novel protein degradation pathway, Kimaritec will develop new anti-cancer therapies.
-
Macrobiome Therapeutics
Macrobiome Therapeutics
Macrobiome Therapeutics Pty Ltd is a company harnessing the therapeutic potential of hookworms and other parasitic helminths to develop drugs for the treatment of immune-mediated inflammatory diseases. The company is based in tropical North Queensland, Australia, an area of enormous biodiversity. Macrobiome Therapeutics was founded by Professor Alex Loukas and Dr Paul Giacomin of the Australian Institute of Tropical Health and Medicine at James Cook University, and brings together a number of leading international medical research teams to develop novel therapeutics for chronic diseases with limited treatment options, such as IBD, T2D, and non-healing wounds. "
-
Michael Buck Intellectual Property
Michael Buck Intellectual Property
Michael Buck IP is an independent, boutique intellectual property firm, based in Brisbane Australia.
We help creative, innovative and inventive people and businesses to protect, defend and commercialise their intellectual assets. Our clients range from local companies and individual inventors to start-ups, international corporations, universities and research organizations.
-
Microba
Microba
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
-
Nucleus Network
Nucleus Network
Nucleus Network, Australia and USA’s Premier Phase I Specialists.
Nucleus Network is the world’s only Phase I clinical trial specialist with clinics in both Australia and the United States. We have three units with 220+ beds and conduct a full suite of complex early phase clinical trials including FIH with biomarkers/patients, DDI, TQT, BA, Biosimilars, Vaccine and Renal/Hepatic Impairment. We are opening a new clinic in Sydney, and expanding our Melbourne clinic. By early 2025 we will be over 300+ beds and have access to ~80% of the Australian population for recruitment!
Operating in the two global regions where a majority of Phase I studies are performed allows our sponsors to exceed their Phase I value inflection targets rapidly, efficiently and meet international quality standards allowing progression into Phase 2 and beyond.
The Australian clinical trial landscape allows global biotechs to advance their clinical programs faster, easier (No IND), cheaper (43.5% Tax Incentive) and to the same quality standard (ICH/GCP) as studies performed in the USA.
-
OneVentures
OneVentures
OneVentures is an Australian based Venture Capital firm with >$750m under management.
OneVentures is a later-stage Venture Capital Firm, focused on scaling Technology and Healthcare companies through growth equity and credit.
-
Pizzeys Patent & Trade Mark Attorneys
Pizzeys Patent & Trade Mark Attorneys
Since 1981, Pizzeys have been providing practical, personalised and responsive service to protect and enforce patents, trade marks and designs. The same committed service is provided in Australia, New Zealand and Singapore.
Our core business resides in establishing, maintaining and enforcing intellectual property rights in Australia, New Zealand and Singapore. Our qualified attorneys are dedicated to achieving the highest of standards. We understand the need for high quality and responsive service.
-
Qbiotics Group
Qbiotics Group
QBiotics is a public unlisted Australian life sciences company that discovers and develops novel small molecule drug candidates. Our current clinical focus is solid tumors and debilitating chronic wounds. QBiotics' lead oncology molecule, tigilanol tiglate, is an intratumoral treatment (usually single injection) for a broad range of solid tumors.
Tigilanol tiglate is very effective as a monotherapy, murine data also supports the potential of tigilanol tiglate in combination with checkpoint inhibitors, chemotherapy and radiotherapy. Tigilanol tiglate is currently in human clinical Phase II development for the treatment of soft tissue sarcomas (USA) (awarded FDA Orphan Drug Designation) and head and neck cancers (UK and Australia).
QBiotics’ business model is to develop drug candidates to proof of concept/human clinical Phase II and then partner for late-stage development and commercialisation. We use veterinary real world disease models (commencing at preclinical stage of development) to validate our technology and de-risks/inform early clinical stage human development. Tigilanol tiglate has secured regulatory and commercial validation as a veterinary product STELFONTA® for canine mast cell tumors, reporting a 75% Complete Response (CR) rate for a single injection in an FDA-CVM pivotal canine trial.
-
Sanofi
Sanofi
Translational Science Hub
The Translational Science Hub connects world-class researchers in Queensland with Sanofi scientists in France and the US, creating a first-of-its-kind, global scientific community focused on mRNA technology and translational science. The Translational Science Hub is proudly supported by Sanofi, Griffith University, The University of Queensland and the Queensland Government.
Our main focus areas:
- Optimise mRNA platform technology: This includes improving mRNA as a vaccine technology that can be used for multiple vaccine candidates and for therapeutics.
- Bring together the local academic and industry network: By having a R&D presence in Australia, Sanofi is able to work more closely with the local scientific talent and help create a strong and sustainable scientific ecosystem.
- Advance the development of vaccine candidates: new vaccines for Influenza, RSV, Chlamydia and Acne are being explored in Queensland.
-
Servatus Biopharmaceuticals
Servatus Biopharmaceuticals
Servatus is an Australian biopharmaceutical company developing dual drug platforms, aiming to deliver first-line and adjunct treatments for select autoimmune, gastrointestinal and dermatological conditions.
Servatus provides:
- Live biotherapeutics design, development, and manufacturing
- Microbiome based therapies for auto-immune conditions
- Clinical stage biotech company
- Proprietary manufacturing process and large scale continuous manufacturing facility with high level of automation
- Over-the-counter products, commercially available for skin conditions.
-
Southern RNA
Southern RNA
Discover Southern RNA, Australia's pioneering Contract Development and Manufacturing Organisation (CDMO) specialising in RNA-based therapeutics and vaccines. Integrate the rapid design turnover of RNA-based drugs with Southern RNA's manufacturing platform and Australia's exceptionally streamlined approval processes to accelerate your path from discovery to clinical trials. Partner with us to fast-track your development journey and leverage the full opportunity of Australia's R&D tax incentive.
Southern RNA has built a team of industry and RNA experts together with a robust pharmaceutical quality system to support a wide range of services, including custom RNA production, tech transfer, engineering run, and clinical-grade manufacturing, analytical assay development (design, qualification, validation), upstream and downstream process development, raw material manufacturing and supply (E. coli cell bank, pDNA, Cap analog).
-
Spruson and Ferguson
Spruson and Ferguson
Spruson & Ferguson is a leading intellectual property firm providing a range of IP services throughout the Asia-Pacific region from our offices in Australia (Brisbane, Melbourne, Sydney), China, (Beijing, Hong Kong), Indonesia, Malaysia, Philippines, Singapore and Thailand.
With a combined team of over 480 people, including patent attorneys, trade mark attorneys and IP lawyers, Spruson & Ferguson is one of the only IP firms with true regional capability, knowledge and experience.
-
Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific provides industry-leading pharma services for drug development, clinical trial logistics, and commercial manufacturing through our Patheon™ brand. We partner with customers in the pharmaceutical, biotech, and life sciences industries as their trusted CDMO to deliver medicine to patients faster. We believe that doing this successfully not only requires science, technology, and world-class expertise, but also requires a strategic partnership—bonded by key elements such as trust, communication, and collaboration. We embed these elements into every operation, interaction, and step in the drug development journey.
With more than 60 locations around the world, we are committed to providing integrated, end-to-end solutions across all phases of development. Our pharma services include API, biologics, viral vectors, formulation, clinical trials solutions, logistics services, and commercial manufacturing, and packaging. We couple our scientific and technical excellence in these areas with a strategic partnership, to provide customers of all sizes access to a global network of facilities and dedicated experts across the Americas, Europe, Asia, and Australia.
At Thermo Fisher Scientific, we understand that developing novel therapies and moving them from discovery to patients is a complex, high-risk process. Every customer has different needs, and every newly discovered drug has a unique pathway to reach the market. As a global, full-service CDMO, we help our partners bring innovative molecules and life-changing therapies to market as efficiently and safely as possible.
-
Thomson Geer Lawyers
Thomson Geer Lawyers
Specialist legal services for the life sciences and health sector in Australia and globally.
We have an in-depth understanding of the life sciences and health sector in Australia and globally.
Our specialist lawyers are experienced in providing advice with respect to the broad range of issues facing this complex and highly regulated industry.
We provide legal services to the broader industry including aged care providers, retirement village operators, affiliated health organisations, primary health networks, public and private hospitals, medical research institutes, start-up companies, spin off companies, private and listed entities, government, universities, international trial sponsors, collaborative research groups, institutions and principal investigators, biotechnology, medical device and pharmaceutical organisations.
This gives us a broad perspective on the whole industry and the range of interactions between sectors.
-
UltraThera
UltraThera
UltraThera is developing therapeutic ultrasound to restore brain function, with Alzheimer's disease as the lead indication. We are at an early clinical stage with proof-of-concept safety using our first generation therapeutic ultrasound system.
We have developed a multimodal therapy that activates the brain's natural immune response and enhances brain cell communication as shown by our extensive preclinical data. The approach has utility across a broad range of neurodegenerative and neurological disorders including delivery of therapeutics to the brain.
-
Vast Bioscience Pty Ltd
Vast Bioscience Pty Ltd
Vast Bioscience is an Australian-based preclinical stage biotech company creating safe and effective non-opioid pain relief options for moderate-to-severe acute and chronic pain through the use of its innovative 3D drug discovery technology. With a focus on genetically and clinically validated Voltage-Gated Sodium Channels (VGSCs), Vast Bioscience has potential to participate in addressing one of the largest unmet medical needs.
Vast Bioscience's chemical platform delivers two new classes of VGSC inhibitors, currently in lead optimisation, that promises to significantly improve efficacy. The small molecules have reduced risk of off-target side effects due to their unique 3D shape. Selective Vast Nav1.8 inhibitors promise improved safety allowing higher exposure and thereby better efficacy towards a best-in-class product.
A parallel program pursues Vast Nav1.7/Nav1.8 selective VGSC inhibitors which are expected to further improve efficacy through synergy between pain VGSCs (first in class).
-
Vaxxas Pty Ltd
Vaxxas Pty Ltd
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP).
With success in several human clinical trials involving more than 500 participants, and additional ongoing studies with its global program partners including BARDA (US Government), the Bill and Melinda Gates Foundation and the WHO, the company is advancing its vaccination technology toward commercialization.
Last updated: 04 Jun 2024